

Trastuzumab emtansine

Cat. No.:	HY-P9921
CAS No.:	1018448-65-1
Target:	Antibody-drug Conjugate (ADC); EGFR
Pathway:	Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer ^{[1][2]} .								
In Vitro	Trastuzumab emtansine (2 µg/mL; 3 d) significantly inhibits the proliferation of epithelial ovarian cancer (EOC) cells ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	<p>Trastuzumab emtansine (15 mg/kg; i.v. three to five times weekly for 3 weeks) exhibits significantly anti-tumor effect in mice^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>CB-17/SCID mice (6 weeks) were injected with OVA10 cells^[2]</td> </tr> <tr> <td>Dosage:</td> <td>15 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>I.v. three to five times weekly for 3 weeks</td> </tr> <tr> <td>Result:</td> <td>Showed remarkable inhibition of tumor growth in mice and was well tolerated.</td> </tr> </table>	Animal Model:	CB-17/SCID mice (6 weeks) were injected with OVA10 cells ^[2]	Dosage:	15 mg/kg	Administration:	I.v. three to five times weekly for 3 weeks	Result:	Showed remarkable inhibition of tumor growth in mice and was well tolerated.
Animal Model:	CB-17/SCID mice (6 weeks) were injected with OVA10 cells ^[2]								
Dosage:	15 mg/kg								
Administration:	I.v. three to five times weekly for 3 weeks								
Result:	Showed remarkable inhibition of tumor growth in mice and was well tolerated.								

REFERENCES

- [1]. Verma S, et, al. Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med*. 2012 Nov 8;367(19):1783-91.
- [2]. Menderes G, et, al. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. *Gynecol Oncol*. 2017 Oct;147(1):145-152.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA